# Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer

> **NCT00284180** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 32 (actual)

## Conditions studied

- Breast Neoplasms
- Breast Cancer

## Interventions

- **DRUG:** Vinflunine
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT00284180
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2008-02
- **Final completion:** 2010-11
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2013-08-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00284180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00284180, "Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00284180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*